BRPI0513082A - formulações de fenofibrato e métodos de tratamento relacionados - Google Patents

formulações de fenofibrato e métodos de tratamento relacionados

Info

Publication number
BRPI0513082A
BRPI0513082A BRPI0513082-4A BRPI0513082A BRPI0513082A BR PI0513082 A BRPI0513082 A BR PI0513082A BR PI0513082 A BRPI0513082 A BR PI0513082A BR PI0513082 A BRPI0513082 A BR PI0513082A
Authority
BR
Brazil
Prior art keywords
omega
treatment methods
solutions
fenofibrate
related treatment
Prior art date
Application number
BRPI0513082-4A
Other languages
English (en)
Inventor
Irn Almarsson
Pasut Ratanabanangkoon
Julius Remenar
Hector Guzman
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of BRPI0513082A publication Critical patent/BRPI0513082A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

FORMULAçõES DE FENOFIBRATO E MéTODOS DE TRATAMENTO RELACIONADOS. A presente invenção refere-se novas soluções de fenofibrato em óleo à base de éster de ómega-3. Estas soluções estão substancialmente isentas de qualquer efeito do alimento, são efetivas em pequenos volumes, e prontamente biodisponíveis. Notavelmente, porque as soluções da invenção contêm um óleo à base de éster de ómega-3 como o ingrediente principal, elas não somente proporcionam um efeito anti-hiperlipidêmico devido ao ingrediente ativo fenofibrato, como também elas proporcionam dosagens diárias recomendadas de óleos de ómega-3 (isto é, aproximadamente 1 grama de óleo de ómega-3 por dia), ou uma sua porção.
BRPI0513082-4A 2004-08-06 2005-08-04 formulações de fenofibrato e métodos de tratamento relacionados BRPI0513082A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US59932004P 2004-08-06 2004-08-06
US60486104P 2004-08-27 2004-08-27
US65576205P 2005-02-24 2005-02-24
US68770405P 2005-06-06 2005-06-06
PCT/US2005/027806 WO2006017692A2 (en) 2004-08-06 2005-08-04 Novel fenofibrate formulations and related methods of treatment

Publications (1)

Publication Number Publication Date
BRPI0513082A true BRPI0513082A (pt) 2008-04-22

Family

ID=35839924

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0513082-4A BRPI0513082A (pt) 2004-08-06 2005-08-04 formulações de fenofibrato e métodos de tratamento relacionados

Country Status (12)

Country Link
US (1) US20090149533A1 (pt)
EP (1) EP1796625A4 (pt)
JP (1) JP2008516890A (pt)
KR (1) KR20070052760A (pt)
AU (1) AU2005271407A1 (pt)
BR (1) BRPI0513082A (pt)
CA (1) CA2573316A1 (pt)
IL (1) IL180739A0 (pt)
MX (1) MX2007001558A (pt)
NZ (1) NZ552390A (pt)
SG (1) SG155189A1 (pt)
WO (1) WO2006017692A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2589654C (en) * 2004-12-06 2016-02-16 Reliant Pharmaceuticals, Inc. Omega-3 fatty acids and dyslipidemic agent for lipid therapy
CN101098690A (zh) * 2004-12-06 2008-01-02 瑞莱恩特医药品有限公司 用于血脂治疗的ω-3脂肪酸和脂血异常剂
NZ569068A (en) * 2005-12-20 2011-11-25 Cenestra Llc Omega 3 fatty acid formulations of EPA and DHA
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
JP2010532418A (ja) * 2007-06-29 2010-10-07 マーテック バイオサイエンシーズ コーポレーション 多価不飽和脂肪酸のエステルの製造方法および精製方法
ES2894340T3 (es) * 2009-03-09 2022-02-14 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un tensioactivo, y métodos y usos de las mismas
CA2972063C (en) 2009-05-22 2019-12-17 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of .omega.3 fatty acid
WO2012037328A2 (en) * 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
US20130203701A1 (en) 2010-09-17 2013-08-08 Maine Natural Health, Inc. Compositions containing omega-3 oil and uses thereof
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
RS57777B1 (sr) 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc Dpa-obogaćene kompozicije omega-3 polinezasićenih masnih kiselina u obliku slobodne kiseline
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
JP6359517B2 (ja) 2012-03-30 2018-07-18 サンシリオ アンド カンパニー, インコーポレイテッドSancilio & Company, Inc. ω−３脂肪酸エステル組成物
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US8722083B2 (en) 2012-06-25 2014-05-13 Mylan, Inc. Fenofibrate formulation
WO2015008848A1 (ja) 2013-07-18 2015-01-22 持田製薬株式会社 ω３脂肪酸の自己乳化組成物
US9801843B2 (en) 2013-07-18 2017-10-31 Mochida Pharmaceutical Co., Ltd. Self-emulsifying composition of ω3 fatty acid
EP2878311A1 (en) * 2013-11-27 2015-06-03 Freund Pharmatec Ltd. Solubility Enhancement for Hydrophobic Drugs
MY185428A (en) 2015-01-21 2021-05-19 Mochida Pharm Co Ltd Self-emulsifying composition of ?-3 fatty acid
KR101719907B1 (ko) * 2015-06-17 2017-03-24 동국대학교 산학협력단 오메가-3 인지질 기반 페노피브레이트 제제 및 이의 제조방법
JP7136807B2 (ja) 2017-04-17 2022-09-13 ザ・ユニバーシティ・オブ・シカゴ ヒトの健康及び疾患の治療用途向けの短鎖脂肪酸の腸への送達用ポリマー材料
CA3212583A1 (en) 2021-03-27 2022-10-06 Daniel Gooding Compositions having improved bioavailability of therapeutics
WO2023174941A1 (en) * 2022-03-14 2023-09-21 TRx Biosciences Limited Fibrate compositions for treating inflammation and neuroinflammation

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5177080A (en) * 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
JP3254219B2 (ja) * 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5861399A (en) * 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US20030153541A1 (en) * 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
WO1999029316A1 (en) * 1997-12-10 1999-06-17 Severson, Mary, L. Pharmaceutical compositions containing an omega-3 fatty acid oil
WO1999029300A1 (en) * 1997-12-10 1999-06-17 Rtp Pharma Inc. Self-emulsifying fenofibrate formulations
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
CA2331640A1 (en) * 1998-05-07 1999-11-11 Elan Corporation Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20070A (sl) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Nove soli inhibitorjev HMG-CoA reduktaze
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US20030104048A1 (en) * 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
AU7984200A (en) * 1999-09-21 2001-04-24 Skyepharma Canada Inc. Surface modified particulate compositions of biologically active substances
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2406574C (en) * 2000-04-10 2006-12-05 Teva Pharmaceutical Industries, Ltd. Stable pharmaceutical compositions containing 7-substituted-3,5-dihydroxyheptanoic acids or 7-substituted-3,5-dihydroxyheptenoic acids
CZ20023826A3 (cs) * 2000-06-09 2003-04-16 Lek Pharmaceuticals D. D. Stabilizovaná farmaceuticky účinná kompozice a léčivý přípravek tuto kompozici obsahující
US6598123B1 (en) * 2000-06-28 2003-07-22 Intel Corporation Snoop filter line replacement for reduction of back invalidates in multi-node architectures
US6667064B2 (en) * 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
US6933291B2 (en) * 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
NZ527408A (en) * 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
ATE358477T1 (de) * 2001-06-12 2007-04-15 Galephar M F Oral anzuwendende arzneizusammensetzung enthaltend ein statinderivat
EP1414496B1 (en) * 2001-08-07 2010-10-20 Galephar M/F Pharmaceutical composition containing a combinaition of ppar-alpha, pravastatin and polyglycolized glyceride
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100414334B1 (ko) * 2001-09-29 2004-01-07 코바이오텍 (주) 프라바스타틴 나트륨의 생산 방법
US6973191B2 (en) * 2001-11-02 2005-12-06 Activcard System and method for generating symmetric keys within a personal security device having minimal trust relationships
US20040018248A1 (en) * 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
WO2003068191A1 (en) * 2002-02-14 2003-08-21 Ranbaxy Laboratories Limited Formulations of atorvastatin stabilized with alkali metal additions
ATE409476T1 (de) * 2002-06-13 2008-10-15 Novartis Pharma Gmbh Calciumsalze von statinen aus indol
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
ATE428411T1 (de) * 2003-11-07 2009-05-15 Jj Pharma Inc Hdl-verstärkende kombinationstherapie-komplexe
US9682043B2 (en) * 2003-12-09 2017-06-20 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20050267197A1 (en) * 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
US20090030077A1 (en) * 2004-08-06 2009-01-29 Transform Pharmaceuticals Inc. Novel Fenofibrate Formulations and Related Methods of Treatment
JP2008509154A (ja) * 2004-08-06 2008-03-27 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド 新規なスタチン薬剤組成物および関連治療方法
EP1830804A2 (en) * 2004-12-06 2007-09-12 Reliant Pharmaceuticals, Inc. Stable compositions of fenofibrate with fatty acid esters
MX2008001597A (es) * 2005-08-04 2008-04-04 Transform Pharmaceuticals Inc Formulaciones novedosas que comprenden fenofibrato y una estatina y metodos relacionados de tratamiento.

Also Published As

Publication number Publication date
WO2006017692A3 (en) 2006-04-06
AU2005271407A1 (en) 2006-02-16
IL180739A0 (en) 2007-06-03
EP1796625A2 (en) 2007-06-20
KR20070052760A (ko) 2007-05-22
NZ552390A (en) 2010-01-29
EP1796625A4 (en) 2009-07-15
SG155189A1 (en) 2009-09-30
WO2006017692A2 (en) 2006-02-16
CA2573316A1 (en) 2006-02-16
US20090149533A1 (en) 2009-06-11
JP2008516890A (ja) 2008-05-22
MX2007001558A (es) 2008-03-13

Similar Documents

Publication Publication Date Title
BRPI0513082A (pt) formulações de fenofibrato e métodos de tratamento relacionados
BRPI0514189A (pt) composições farmacêuticas de estatina e métodos de tratamento relacionados
BRPI0515316A (pt) compostos de imidazoquinolina
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
MA29860B1 (fr) Modulateurs du metabolisme et le traitement de troubles s'y rapportant
EA200970081A1 (ru) Соединения, обладающие потенциирующим действием в отношении активности этионамида, и их применения
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
MX2009003305A (es) Inhibidores de co-transportador de glucosa de sodio 2 y metodo para su uso.
IL219721A0 (en) Charged lipoprotein complexes, pharmaceutical compositions comprising them and their uses
TR200003736T2 (tr) Anksiyete durumlarına ya da depresyona bağlı değişikliklerin önlenmesi
SI1680128T1 (sl) Mio-inozitol heksafosfat za topično uporabo
BRPI0212298B8 (pt) composição farmacêutica compreendendo gabapentina ou um análogo da mesma e (alfa)-aminoamida e seu uso analgésico
CO6150156A2 (es) Esteres de dha y su utilizacion en el tratamiento y la prevencion de enfermedades cardiovasculares
EP2241196A3 (en) Nutritional supplement comprising oligosaccharides and cysteine for treating hiv
MX2008004734A (es) Composicion rica en leucina.
MXPA06010767A (es) Composicion farmaceutica anhidra que asocia un agente siliconado y principio activo solubilizado.
UY29236A1 (es) 2-alcoxi-3,4,5-trihidroxi-alquilamidas. su preparación, composiciones que las contienen y su utilización.
TW200719920A (en) Topical skin care composition
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
ATE358992T1 (de) Enteralpräparat zur vorbeugung gegen bzw. behandlung von sepsis
BRPI0410761A (pt) uso de leucina, e, composição para administração entérica a pacientes
BRPI0715740A8 (pt) Agente redutor de triglicerídeos séricos
FR2887150B1 (fr) Composition pharmaceutique comprenant un elastomere organopolysiloxane et un principe actif solubilise
MXPA05010704A (es) Composiciones farmaceuticas que comprenden un inmunomodulador de macrolido.
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.